U.S. markets open in 5 hours 35 minutes
  • S&P Futures

    3,939.75
    +23.50 (+0.60%)
     
  • Dow Futures

    31,642.00
    +155.00 (+0.49%)
     
  • Nasdaq Futures

    12,232.75
    +92.25 (+0.76%)
     
  • Russell 2000 Futures

    1,772.80
    +11.10 (+0.63%)
     
  • Crude Oil

    107.71
    +0.09 (+0.08%)
     
  • Gold

    1,837.70
    +7.40 (+0.40%)
     
  • Silver

    21.43
    +0.31 (+1.47%)
     
  • EUR/USD

    1.0591
    +0.0032 (+0.31%)
     
  • 10-Yr Bond

    3.1250
    0.0000 (0.00%)
     
  • Vix

    28.33
    -0.72 (-2.48%)
     
  • GBP/USD

    1.2326
    +0.0056 (+0.46%)
     
  • USD/JPY

    135.0170
    -0.1530 (-0.11%)
     
  • BTC-USD

    21,321.87
    -62.81 (-0.29%)
     
  • CMC Crypto 200

    465.37
    +11.47 (+2.53%)
     
  • FTSE 100

    7,266.83
    +58.02 (+0.80%)
     
  • Nikkei 225

    26,871.27
    +379.30 (+1.43%)
     

Investors one-year losses grow to 56% as the stock sheds US$10m this past week

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

It is a pleasure to report that the Aziyo Biologics, Inc. (NASDAQ:AZYO) is up 57% in the last quarter. But that doesn't change the fact that the returns over the last year have been disappointing. Like a receding glacier in a warming world, the share price has melted 56% in that period. It's not that amazing to see a bounce after a drop like that. It may be that the fall was an overreaction.

Given the past week has been tough on shareholders, let's investigate the fundamentals and see what we can learn.

See our latest analysis for Aziyo Biologics

Aziyo Biologics wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. When a company doesn't make profits, we'd generally expect to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

Aziyo Biologics grew its revenue by 11% over the last year. While that may seem decent it isn't great considering the company is still making a loss. It's likely this muted growth has contributed to the share price decline of 56% in the last year. We'd want to see evidence that future revenue growth will be stronger before getting too interested. When a stock falls hard like this, it can signal an over-reaction. Our preference is to wait for a fundamental improvements before buying, but now could be a good time for some research.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

earnings-and-revenue-growth
earnings-and-revenue-growth

It's probably worth noting we've seen significant insider buying in the last quarter, which we consider a positive. On the other hand, we think the revenue and earnings trends are much more meaningful measures of the business. This free report showing analyst forecasts should help you form a view on Aziyo Biologics

A Different Perspective

While Aziyo Biologics shareholders are down 56% for the year, the market itself is up 4.7%. While the aim is to do better than that, it's worth recalling that even great long-term investments sometimes underperform for a year or more. Putting aside the last twelve months, it's good to see the share price has rebounded by 57%, in the last ninety days. This could just be a bounce because the selling was too aggressive, but fingers crossed it's the start of a new trend. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Case in point: We've spotted 4 warning signs for Aziyo Biologics you should be aware of.

Aziyo Biologics is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.